Bristol-Myers Squibb Company (BMY) Q3 2026 (USD): Adj. EPS 1.35 (exp. 1.10), Revenue 13.07bln (exp. 12.72bln)
ORIGINAL · NewsquawkBristol-Myers Squibb Company (BMY) Q3 2026 (USD): Adj. EPS 1.35 (exp. 1.10), Revenue 13.07bln (exp. 12.72bln)Read originalHide original
Other Metrics: Growth Portfolio revenue 7.66bln, +12% Y/Y. Legacy Portfolio revenue 5.42bln, +1% Y/Y. Eliquis revenue 4.69bln, +25% Y/Y. US revenue 9.07bln, +9% Y/Y. International revenue 4.0bln, +3% Y/Y. FY outlook Adj. EPS 6.35-6.55 (exp. 6.34), Revenue 49.75-50.25bln (exp. 49.9bln). Commentary: Growth Portfolio performance was driven by Opdivo Qvantig, Breyanzi, Reblozyl, Camzyos and Opdualag, while Eliquis growth offset continued generic competition in the Legacy Portfolio.
Bristol Myers Squibb reported Q3 growth across stated portfolios and geographies, while Reuters described lower EPS and higher revenue guidance versus prior ranges and cited a quarterly charge.
News detail
Other Metrics: Growth Portfolio revenue 7.66bln, +12% Y/Y. Legacy Portfolio revenue 5.42bln, +1% Y/Y. Eliquis revenue 4.69bln, +25% Y/Y. US revenue 9.07bln, +9% Y/Y. International revenue 4.0bln, +3% Y/Y. FY outlook Adj. EPS 6.35-6.55 (exp. 6.34), Revenue 49.75-50.25bln (exp. 49.9bln). Commentary: Growth Portfolio performance was driven by Opdivo Qvantig, Breyanzi, Reblozyl, Camzyos and Opdualag, while Eliquis growth offset continued generic competition in the Legacy Portfolio.
Related stocks
1 stocksWhat do investors think?
StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
